Shuxia Guo Selected Research

Inflammation (Inflammations)

12/2020	Complement 1q protects MRL/lpr mice against lupus nephritis via inhibiting the nuclear factor-κB pathway.
5/2020	Quercetin alleviates lipopolysaccharide-induced inflammatory responses by up-regulation miR-124 in human renal tubular epithelial cell line HK-2.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shuxia Guo Research Topics

Disease

6	Hypertension (High Blood Pressure) 01/2022 - 01/2015
4	Obesity 01/2022 - 01/2015
4	Dyslipidemias (Dyslipidemia) 01/2019 - 09/2015
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 05/2015
3	Type 2 Diabetes Mellitus (MODY) 10/2015 - 01/2015
2	Inflammation (Inflammations) 12/2020 - 05/2020
2	Abdominal Obesity 12/2017 - 01/2016
2	Overweight 01/2016 - 01/2015
2	Essential Hypertension 08/2010 - 05/2007
1	Fabry Disease (Fabry's Disease) 05/2022
1	Insulin Resistance 01/2022
1	Lymphoma (Lymphomas) 01/2022
1	Hypotension (Low Blood Pressure) 01/2022
1	Psoriasis (Pustulosis Palmaris et Plantaris) 02/2021
1	Skeletal Abnormalities Mandibular Hypoplasia Auditory Canal Atresia Short Stature 01/2021
1	Lupus Nephritis 12/2020
1	Necrosis 12/2020
1	Neoplasms (Cancer) 12/2020
1	Cardiomyopathies (Cardiomyopathy) 01/2020
1	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 01/2020
1	Cysts 01/2020
1	Diabetic Nephropathies (Diabetic Nephropathy) 10/2018
1	Hypercholesterolemia 01/2016
1	Hypertriglyceridemia 01/2016
1	Hyperlipidemias (Hyperlipidemia) 01/2016
1	Vascular Diseases (Vascular Disease) 05/2015
1	Hyperhomocysteinemia 05/2015
1	Isolated Systolic Hypertension 05/2015
1	Blood Coagulation Disorders 05/2015
1	Acute Promyelocytic Leukemia 05/2015
1	Diabetes Mellitus 01/2015
1	Liver Diseases (Liver Disease) 01/2015

Drug/Important Bio-Agent (IBA)

5	LipidsIBA 05/2022 - 01/2015
3	Blood Glucose (Blood Sugar)IBA 01/2022 - 01/2017
3	Triglycerides (Triacylglycerol)IBA 01/2022 - 01/2015
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 08/2010
3	HDL CholesterolIBA 12/2017 - 01/2016
3	Glucagon-Like Peptide-1 Receptor AgonistsIBA 10/2015 - 01/2015
2	EnzymesIBA 01/2022 - 01/2021
2	CytokinesIBA 01/2021 - 01/2019
2	Glucose (Dextrose)FDA LinkGeneric 12/2017 - 01/2015
2	oxidized low density lipoproteinIBA 01/2016 - 12/2015
1	globotriaosylceramide (globotriosylceramide)IBA 05/2022
1	pegaspargase (Oncaspar)FDA Link 01/2022
1	HDL LipoproteinsIBA 01/2022
1	Gemcitabine FDA Link 01/2022
1	Asparaginase (Elspar)FDA Link 01/2022
1	Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)IBA 01/2022
1	Cisplatin (Platino)FDA LinkGeneric 01/2022
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022
1	ORALIT (ORS)IBA 01/2022
1	Lipoproteins (Lipoprotein)IBA 01/2022
1	Cysteine (L-Cysteine)FDA Link 01/2021
1	phorbolIBA 12/2020
1	DNA (Deoxyribonucleic Acid)IBA 12/2020
1	InterleukinsIBA 12/2020
1	Complement C1q (C1q Complement)IBA 12/2020
1	QuercetinIBA 05/2020
1	HCEIBA 01/2020
1	Pharmaceutical PreparationsIBA 01/2020
1	AdiponectinIBA 01/2019
1	Interleukin-6 (Interleukin 6)IBA 01/2019
1	Transcription Factors (Transcription Factor)IBA 10/2018
1	CholesterolIBA 01/2018
1	LDL CholesterolIBA 01/2016
1	cerivastatin (Kazak)FDA Link 12/2015
1	Cholesterol Ester Transfer ProteinsIBA 12/2015
1	Exenatide (Byetta)FDA Link 10/2015
1	Hypoglycemic Agents (Hypoglycemics)IBA 10/2015
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 09/2015
1	HomocysteineIBA 05/2015
1	Biomarkers (Surrogate Marker)IBA 05/2015
1	Arsenic Trioxide (Trisenox)FDA Link 05/2015
1	Daunorubicin (Cerubidine)FDA LinkGeneric 05/2015
1	Annexin A2 (Annexin II)IBA 05/2015
1	Drug CombinationsIBA 05/2015
1	ArsenicIBA 01/2015
1	AntioxidantsIBA 01/2015
1	LuteinIBA 01/2015
1	Transforming Growth Factor beta1 (TGF beta 1)IBA 08/2010
1	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 05/2007

Therapy/Procedure

3	Therapeutics 02/2021 - 01/2015
1	Drug Therapy (Chemotherapy) 01/2022
1	Heart Transplantation (Grafting, Heart) 01/2020